NO820403L - Cytoreseptor-maalemetode. - Google Patents
Cytoreseptor-maalemetode.Info
- Publication number
- NO820403L NO820403L NO820403A NO820403A NO820403L NO 820403 L NO820403 L NO 820403L NO 820403 A NO820403 A NO 820403A NO 820403 A NO820403 A NO 820403A NO 820403 L NO820403 L NO 820403L
- Authority
- NO
- Norway
- Prior art keywords
- analyte
- cells
- labeled
- liquid
- medium
- Prior art date
Links
- 238000000691 measurement method Methods 0.000 title description 4
- 239000012491 analyte Substances 0.000 claims abstract description 55
- 238000003556 assay Methods 0.000 claims abstract description 9
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 66
- 238000004458 analytical method Methods 0.000 claims description 19
- 239000002609 medium Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 238000002372 labelling Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 210000000172 cytosol Anatomy 0.000 claims description 4
- 102000002572 Alpha-Globulins Human genes 0.000 claims description 3
- 108010068307 Alpha-Globulins Proteins 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 claims description 2
- 239000012911 assay medium Substances 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000538 analytical sample Substances 0.000 claims 1
- 230000009172 bursting Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000872 buffer Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 108700021020 Vitamin D-binding protein Proteins 0.000 description 1
- 239000003242 anti bacterial agent Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/161,462 US4375459A (en) | 1980-06-20 | 1980-06-20 | Cytoreceptor assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO820403L true NO820403L (no) | 1982-02-11 |
Family
ID=22581269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO820403A NO820403L (no) | 1980-06-20 | 1982-02-11 | Cytoreseptor-maalemetode. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4375459A (fr) |
| EP (1) | EP0042673B1 (fr) |
| JP (1) | JPS5728257A (fr) |
| AT (1) | ATE18805T1 (fr) |
| CA (1) | CA1155373A (fr) |
| DE (1) | DE3174170D1 (fr) |
| DK (1) | DK72082A (fr) |
| NO (1) | NO820403L (fr) |
| WO (1) | WO1982000059A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544629A (en) * | 1982-11-19 | 1985-10-01 | Minnesota Mining And Manufacturing Company | Receptor-based histamine assay |
| US4497791A (en) * | 1983-02-10 | 1985-02-05 | Vestar Research Incorporated | Method for labeling phagocytic cells |
| US5100774A (en) * | 1988-04-22 | 1992-03-31 | The Wistar Institute Of Anatomy & Biology | Methods for detecting growth factor receptor expression |
| US5759774A (en) * | 1988-05-18 | 1998-06-02 | Cobe Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells |
| CA1335707C (fr) * | 1989-08-15 | 1995-05-30 | Pyare Khanna | Test de depistage de l'usage de drogues |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1039649A (fr) * | 1973-08-30 | 1978-10-03 | General Electric Company | Methode pour former des films d'un complexe immunologique en plusieurs couches |
| US4247536A (en) * | 1978-03-20 | 1981-01-27 | American Hospital Supply Corporation | Method of preparing C3-sensitized erythrocytes |
| NZ190452A (en) * | 1978-05-19 | 1981-04-24 | Becton Dickinson Co | Solid phase assay receptor contacted with analyte and then with labeled analyte |
| FR2415303A1 (fr) * | 1978-05-31 | 1979-08-17 | Ferrosan As | Procede pour la determination de la concentration de benzodiazepines dans un fluide de l'organisme |
| US4282315A (en) * | 1979-09-13 | 1981-08-04 | Corning Glass Works | Preparation of enriched whole virus radioligand |
-
1980
- 1980-06-20 US US06/161,462 patent/US4375459A/en not_active Expired - Lifetime
-
1981
- 1981-05-20 CA CA000377922A patent/CA1155373A/fr not_active Expired
- 1981-06-01 AT AT81302400T patent/ATE18805T1/de not_active IP Right Cessation
- 1981-06-01 EP EP81302400A patent/EP0042673B1/fr not_active Expired
- 1981-06-01 DE DE8181302400T patent/DE3174170D1/de not_active Expired
- 1981-06-19 WO PCT/US1981/000833 patent/WO1982000059A1/fr not_active Ceased
- 1981-06-19 JP JP9411681A patent/JPS5728257A/ja active Pending
-
1982
- 1982-02-11 NO NO820403A patent/NO820403L/no unknown
- 1982-02-19 DK DK72082A patent/DK72082A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1982000059A1 (fr) | 1982-01-07 |
| DK72082A (da) | 1982-02-19 |
| CA1155373A (fr) | 1983-10-18 |
| DE3174170D1 (en) | 1986-04-30 |
| US4375459A (en) | 1983-03-01 |
| JPS5728257A (en) | 1982-02-15 |
| ATE18805T1 (de) | 1986-04-15 |
| EP0042673A1 (fr) | 1981-12-30 |
| EP0042673B1 (fr) | 1986-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6787660B1 (en) | Functional vitamin D derivatives and a method for determining 25-hydroxy-vitamin D and 1α, dihydroxy-vitamin D | |
| US8133694B2 (en) | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D | |
| US4146602A (en) | Simultaneous radioassay of folate and vitamin B12 | |
| US4279859A (en) | Simultaneous radioassay of folate and vitamin B12 | |
| CN109187971A (zh) | 神经元特异性烯醇化酶化学发光免疫检测试剂盒及其制备方法 | |
| US5814461A (en) | Method for the determination of anti-TSH receptor autoantibodies | |
| NO820403L (no) | Cytoreseptor-maalemetode. | |
| US4355018A (en) | Assay for vitamin B12 | |
| Zhou et al. | A new sensitive method for the detection of chloramphenicol in food using time-resolved fluoroimmunoassay | |
| KR20160126055A (ko) | 당쇄를 포함하는 표적 물질의 검출용 시약, 검출 방법, 및 당쇄를 포함하는 표적 물질을 검출하기 위해서 이용되는 담체 및 그 제조 방법 | |
| FI78787B (fi) | Immunometrisk metod foer bestaemning av en hapten. | |
| US7279283B1 (en) | Cobalamin assay | |
| US4300907A (en) | Serum vitamin B12 assay and kit therefor | |
| US20020132256A1 (en) | Method for the detection and measurement of hapten-conjugated biological binding entities by western and dot-blot using anti-hapten antibodies | |
| US5437981A (en) | Method for the immunological determination of ligands | |
| Joshi et al. | Penicillinase as a marker in enzyme-linked immunosorbent assays for steroid hormones | |
| CA1098015A (fr) | Dosage par la methode radioisotopique du folate et de la vitamine b in12 xx simultanement | |
| US4399228A (en) | Polate competitive protein binding assay | |
| EP1257830B1 (fr) | Dosage biologique servant a la mesure de l'holotranscobalamine et du folate | |
| CA2034922A1 (fr) | Methode de determination immunologique des ligands | |
| AU2003203209B2 (en) | Cobalamin assay | |
| Arnaud et al. | Microassay for 25-hydroxyvitamin D: method and interpretation | |
| Gutcho et al. | Simultaneous radioassay of folate and vitamin B12 | |
| ZA200101937B (en) | Cobalamin assay. | |
| HU202322B (en) | Method for radioimmunological determination of 3'-asido-3'-desoxi-thymidine content of biological samples |